

Appendix E. Aim 2 Full Sample Analyses

Appendix E: Aim 2 Full Sample Analyses

Tables - Change in Outcomes

Unweighted Changes in Weight

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	205.89	208.31	2.42	(2.3266,2.5135)	<.0001	1.17541
Quetiapine	205.53	207.72	2.1873	(2.0756,2.2991)	<.0001	1.06425
Risperidone	208.49	211.19	2.6972	(2.5279,2.8666)	<.0001	1.29368
Olanzapine	196.49	200.21	3.7247	(3.3325,4.1169)	<.0001	1.89567
Mirtazapine	201.95	205.16	3.2115	(3.1098,3.3131)	<.0001	1.59027
Prazosin	212.47	214.18	1.7104	(1.6371,1.7838)	<.0001	0.80505
Tricyclics	210.05	212.14	2.0841	(1.9328,2.2354)	<.0001	0.99216
Amitriptyline	210.04	212.2	2.1524	(1.9973,2.3075)	<.0001	1.02473
Imipramine	210.23	211.01	0.7862	(0.153,1.4194)	0.015	0.37397

Propensity Score Weighted Changes in Weight

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	206.52	208.83	2.3034	(2.2095,2.3973)	<.0001	1.11531
Quetiapine	206.12	208.19	2.0655	(1.9533,2.1776)	<.0001	1.00205
Risperidone	209.08	211.66	2.5854	(2.4158,2.7549)	<.0001	1.23657
Olanzapine	197.46	201.13	3.6622	(3.2704,4.0541)	<.0001	1.85464
Mirtazapine	202.53	205.89	3.3645	(3.2627,3.4662)	<.0001	1.66122
Prazosin	211.98	213.65	1.6718	(1.5971,1.7466)	<.0001	0.78867
Tricyclics	209.4	211.52	2.1188	(1.9595,2.2781)	<.0001	1.01182
Amitriptyline	209.44	211.61	2.1758	(2.0122,2.3394)	<.0001	1.03891
Imipramine	209.07	210.2	1.1296	(0.4926,1.7665)	0.0005	0.54028

Number of Windows for Weight

Medication Group	n(pre)	n(post)
Antipsychotics	67559	67024
Quetiapine	44878	44609
Risperidone	18673	18476
Olanzapine	4008	3939
Mirtazapine	52415	51706
Prazosin	95224	93714
Tricyclics	21443	21161
Amitriptyline	20379	20097
Imipramine	1064	1064

Number of Weight Measurements per Person

	Pre-Index Year	Post-Index Year
	Median (IQR)	Median (IQR)
Antipsychotics	4(2,7)	5(3,8)
Mirtazapine	4(2,7)	4(2,7)
Prazosin	4(2,6)	4(2,7)
Tricyclics	5(3,8)	5(3,8)

Unweighted Changes in A1c

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	6.1122	6.1553	0.04307	(0.0334,0.0527)	<.0001	0.70465
Quetiapine	6.0906	6.1303	0.03974	(0.0278,0.0517)	<.0001	0.65241
Risperidone	6.1888	6.2285	0.03963	(0.0208,0.0585)	<.0001	0.6403
Olanzapine	5.9993	6.0781	0.07876	(0.039,0.1186)	0.0001	1.31287
Mirtazapine	6.1777	6.3077	0.13	(0.1182,0.1418)	<.0001	2.10385
Prazosin	6.197	6.2133	0.01635	(0.0083,0.0244)	<.0001	0.26378
Tricyclics	6.3316	6.4046	0.073	(0.0544,0.0916)	<.0001	1.15289
Amitriptyline	6.3391	6.4127	0.07357	(0.0543,0.0928)	<.0001	1.16052
Imipramine	6.2032	6.2724	0.06922	(0.003,0.1354)	0.0405	1.11583

Propensity Score Weighted Changes in A1c

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	6.134	6.1758	0.04181	(0.0322,0.0515)	<.0001	0.68166
Quetiapine	6.1107	6.1483	0.03755	(0.0255,0.0496)	<.0001	0.61448
Risperidone	6.2116	6.2516	0.04001	(0.0211,0.0589)	<.0001	0.64419
Olanzapine	6.0203	6.1047	0.08438	(0.0444,0.1244)	<.0001	1.40155
Mirtazapine	6.1443	6.2741	0.1298	(0.1181,0.1416)	<.0001	2.11309
Prazosin	6.2279	6.2428	0.01488	(0.0066,0.0231)	0.0004	0.23887
Tricyclics	6.2349	6.3144	0.07958	(0.0615,0.0977)	<.0001	1.27641
Amitriptyline	6.241	6.3205	0.07952	(0.0608,0.0982)	<.0001	1.27416
Imipramine	6.1446	6.2315	0.08694	(0.0191,0.1547)	0.0121	1.41492

Number of Windows for A1c

Medication Group	n(pre)	n(post)
Antipsychotics	35113	39973
Quetiapine	23100	26363
Risperidone	10025	11381
Olanzapine	1988	2229
Mirtazapine	28492	29069
Prazosin	52778	53883
Tricyclics	12070	12167
Amitriptyline	11470	11526
Imipramine	600	641

Unweighted Changes in Glucose

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	110.85	112.93	2.0832	(1.7823,2.3841)	<.0001	1.87929
Quetiapine	110.3	112.05	1.7487	(1.3838,2.1137)	<.0001	1.58544
Risperidone	112.55	114.99	2.4355	(1.8249,3.0462)	<.0001	2.16396
Olanzapine	108.26	112.4	4.1461	(2.9207,5.3715)	<.0001	3.82989
Mirtazapine	111.97	115.45	3.4846	(3.138,3.8313)	<.0001	3.11214
Prazosin	111.96	113.6	1.6388	(1.3851,1.8925)	<.0001	1.46369
Tricyclics	114.93	117.19	2.2648	(1.7095,2.8201)	<.0001	1.97062
Amitriptyline	115.06	117.36	2.3024	(1.7268,2.878)	<.0001	2.00106
Imipramine	112.57	114.2	1.637	(-0.3682,3.6422)	0.1095	1.45426

Propensity Score Weighted Changes in Glucose

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	111.21	113.34	2.123	(1.82,2.426)	<.0001	1.90893
Quetiapine	110.62	112.41	1.7857	(1.4182,2.1533)	<.0001	1.61425
Risperidone	112.94	115.39	2.4502	(1.8367,3.0636)	<.0001	2.16948
Olanzapine	108.71	113.06	4.3528	(3.1165,5.5891)	<.0001	4.004
Mirtazapine	110.86	114.27	3.4105	(3.0705,3.7504)	<.0001	3.07635
Prazosin	112.91	114.51	1.6067	(1.3471,1.8664)	<.0001	1.42309
Tricyclics	112.66	114.76	2.097	(1.5661,2.628)	<.0001	1.86139
Amitriptyline	112.76	114.84	2.0825	(1.5314,2.6336)	<.0001	1.84686
Imipramine	111.15	113.58	2.4273	(0.5639,4.2907)	0.0107	2.18377

Number of Windows for Glucose

Medication Group	n(pre)	n(post)
Antipsychotics	61042	60508
Quetiapine	40382	40050
Risperidone	17015	16890
Olanzapine	3645	3568
Mirtazapine	47878	46593
Prazosin	85482	82938
Tricyclics	19702	19119
Amitriptyline	18705	18132
Imipramine	997	987

Unweighted Changes in Triglycerides

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	171.79	180.56	8.7678	(7.7603,9.7752)	<.0001	5.10376
Quetiapine	171.57	182.08	10.5086	(9.2418,11.7755)	<.0001	6.12498
Risperidone	174.25	177.39	3.1359	(1.323,4.9488)	0.0007	1.79964
Olanzapine	168.48	185.02	16.5381	(11.8652,21.2109)	<.0001	9.8158
Mirtazapine	168.46	181.16	12.7049	(11.5198,13.89)	<.0001	7.54191
Prazosin	174.91	175.35	0.4451	(-0.4383,1.3286)	0.3234	0.2545
Tricyclics	182.47	187.74	5.2725	(3.3926,7.1524)	<.0001	2.88951
Amitriptyline	182.66	188.28	5.621	(3.6728,7.5693)	<.0001	3.07724
Imipramine	179.79	178.75	-1.0398	(-7.4872,5.4076)	0.7516	-0.57836

Propensity Score Weighted Changes in Triglycerides

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	171.61	180	8.3926	(7.398,9.3872)	<.0001	4.89058
Quetiapine	171.43	181.58	10.1514	(8.9024,11.4003)	<.0001	5.92162
Risperidone	174.07	176.84	2.768	(0.982,4.5541)	0.0024	1.59018
Olanzapine	168.43	184.66	16.2295	(11.5653,20.8936)	<.0001	9.63564
Mirtazapine	169.22	182.13	12.9079	(11.7091,14.1067)	<.0001	7.6278
Prazosin	175.67	175.79	0.1191	(-0.7731,1.0112)	0.7936	0.06777
Tricyclics	180.07	185.55	5.4738	(3.6514,7.2962)	<.0001	3.0398
Amitriptyline	180.34	186.22	5.8804	(3.9877,7.7732)	<.0001	3.26067
Imipramine	176.52	175.05	-1.4656	(-7.7031,4.772)	0.6447	-0.83027

Number of Windows for Triglycerides

Medication Group	n(pre)	n(post)
Antipsychotics	56328	56373
Quetiapine	37218	37370
Risperidone	15758	15739
Olanzapine	3352	3264
Mirtazapine	44491	42654
Prazosin	79312	76375
Tricyclics	18115	17281
Amitriptyline	17208	16387
Imipramine	907	894

Unweighted Changes in HDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	43.9705	43.6116	-0.3589	(-0.4403,-0.2776)	<.0001	-0.81629
Quetiapine	44.1311	43.6625	-0.4687	(-0.5722,-0.3651)	<.0001	-1.06196
Risperidone	43.4715	43.3334	-0.1381	(-0.283,0.0068)	0.0617	-0.31775
Olanzapine	44.0157	43.6802	-0.3355	(-0.6843,0.0133)	0.0594	-0.76221
Mirtazapine	44.4734	43.9222	-0.5512	(-0.6474,-0.4551)	<.0001	-1.23943
Prazosin	43.9016	43.9003	-0.00131	(-0.0666,0.064)	0.9687	-0.00298
Tricyclics	43.3031	43.2571	-0.04597	(-0.1824,0.0905)	0.509	-0.10617
Amitriptyline	43.2633	43.1685	-0.09485	(-0.2351,0.0454)	0.185	-0.21923
Imipramine	43.9537	44.8262	0.8725	(0.2772,1.4677)	0.0041	1.98502

Propensity Score Weighted Changes in HDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	44.0194	43.7078	-0.3115	(-0.3922,-0.2308)	<.0001	-0.70773
Quetiapine	44.16	43.7498	-0.4102	(-0.5129,-0.3074)	<.0001	-0.92881
Risperidone	43.5471	43.437	-0.1101	(-0.2536,0.0334)	0.1327	-0.25283
Olanzapine	44.1259	43.8051	-0.3208	(-0.6674,0.0259)	0.0697	-0.72693
Mirtazapine	44.3987	43.839	-0.5597	(-0.6552,-0.4642)	<.0001	-1.26061
Prazosin	43.9049	43.9044	-0.0005	(-0.0667,0.0657)	0.9883	-0.00113
Tricyclics	43.171	43.072	-0.09896	(-0.2387,0.0407)	0.165	-0.22923
Amitriptyline	43.1331	42.9741	-0.159	(-0.3023,-0.0157)	0.0296	-0.36869
Imipramine	43.7201	44.646	0.9258	(0.2977,1.554)	0.0039	2.11766

Number of Windows for HDL Cholesterol

Medication Group	n(pre)	n(post)
Antipsychotics	55849	56068
Quetiapine	36942	37169
Risperidone	15594	15653
Olanzapine	3313	3246
Mirtazapine	44142	42394
Prazosin	78800	75999
Tricyclics	18026	17238
Amitriptyline	17124	16343
Imipramine	902	895

Unweighted Changes in LDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	109.52	107.84	-1.6808	(-1.9306,-1.431)	<.0001	-1.5347
Quetiapine	109.96	108.18	-1.7878	(-2.0987,-1.4769)	<.0001	-1.62581
Risperidone	108.79	106.89	-1.9077	(-2.3754,-1.44)	<.0001	-1.75352
Olanzapine	108.49	108.85	0.3565	(-0.7396,1.4526)	0.5237	0.32856
Mirtazapine	106.96	105.69	-1.271	(-1.558,-0.984)	<.0001	-1.18832
Prazosin	109.41	106.77	-2.6459	(-2.8562,-2.4356)	<.0001	-2.41828
Tricyclics	108.98	106.57	-2.416	(-2.8613,-1.9708)	<.0001	-2.2169
Amitriptyline	109.07	106.6	-2.4696	(-2.9278,-2.0114)	<.0001	-2.26426
Imipramine	107.37	105.93	-1.4441	(-3.2918,0.4036)	0.1254	-1.34493

Propensity Score Weighted Changes in LDL Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	109.14	107.46	-1.682	(-1.931,-1.4329)	<.0001	-1.54117
Quetiapine	109.64	107.84	-1.7961	(-2.106,-1.4863)	<.0001	-1.6382
Risperidone	108.32	106.43	-1.8927	(-2.3588,-1.4265)	<.0001	-1.74728
Olanzapine	108.16	108.53	0.3705	(-0.7288,1.4699)	0.5088	0.34256
Mirtazapine	108.03	106.81	-1.2228	(-1.5095,-0.9362)	<.0001	-1.13188
Prazosin	108.99	106.32	-2.6737	(-2.885,-2.4624)	<.0001	-2.45309
Tricyclics	109.39	106.99	-2.4004	(-2.8444,-1.9563)	<.0001	-2.19427
Amitriptyline	109.51	107.07	-2.437	(-2.8942,-1.9798)	<.0001	-2.22539
Imipramine	107.52	105.59	-1.9378	(-3.7711,-0.1045)	0.0383	-1.80216

Number of Windows for LDL Cholesterol

Medication Group	n(pre)	n(post)
Antipsychotics	55430	55649
Quetiapine	36632	36891
Risperidone	15503	15532
Olanzapine	3295	3226
Mirtazapine	43859	42200
Prazosin	78523	75777
Tricyclics	17845	17102
Amitriptyline	16951	16214
Imipramine	894	888

Unweighted Changes in Total Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	184.66	183.82	-0.8419	(-1.1341,-0.5496)	<.0001	-0.45589
Quetiapine	185.21	184.48	-0.7271	(-1.0906,-0.3637)	<.0001	-0.3926
Risperidone	183.83	182.11	-1.7127	(-2.2583,-1.167)	<.0001	-0.93167
Olanzapine	183.6	185.32	1.7202	(0.4339,3.0065)	0.0088	0.9369
Mirtazapine	182.05	181.84	-0.2058	(-0.5468,0.1352)	0.2368	-0.11305
Prazosin	184.82	181.95	-2.8791	(-3.1263,-2.632)	<.0001	-1.55776
Tricyclics	185.02	182.98	-2.038	(-2.562,-1.514)	<.0001	-1.10153
Amitriptyline	185.14	183.09	-2.051	(-2.5894,-1.5127)	<.0001	-1.10784
Imipramine	182.77	180.92	-1.8496	(-4.0656,0.3665)	0.1017	-1.01195

Propensity Score Weighted Changes in Total Cholesterol

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	184.28	183.42	-0.8597	(-1.1514,-0.5681)	<.0001	-0.46655
Quetiapine	184.88	184.12	-0.7543	(-1.1165,-0.3921)	<.0001	-0.40801
Risperidone	183.35	181.65	-1.7018	(-2.2473,-1.1563)	<.0001	-0.92818
Olanzapine	183.34	185.05	1.706	(0.418,2.9939)	0.0094	0.93051
Mirtazapine	183.21	183.07	-0.1427	(-0.4831,0.1976)	0.411	-0.07791
Prazosin	184.54	181.61	-2.9317	(-3.1804,-2.6831)	<.0001	-1.58867
Tricyclics	184.9	182.87	-2.0232	(-2.5446,-1.5018)	<.0001	-1.09423
Amitriptyline	185.06	183.05	-2.0111	(-2.5465,-1.4757)	<.0001	-1.08671
Imipramine	182.1	179.71	-2.3905	(-4.6346,-0.1464)	0.0368	-1.31276

Number of Windows for Total Cholesterol

Medication Group	n(pre)	n(post)
Antipsychotics	55195	55478
Quetiapine	36586	36846
Risperidone	15319	15399
Olanzapine	3290	3233
Mirtazapine	43672	42009
Prazosin	78020	75192
Tricyclics	17847	17081
Amitriptyline	16962	16200
Imipramine	885	881

Unweighted Changes in Systolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	129.31	128.69	-0.6129	(-0.6923,-0.5334)	<.0001	-0.47397
Quetiapine	129.29	128.82	-0.4691	(-0.567,-0.3712)	<.0001	-0.36281
Risperidone	129.36	128.3	-1.0589	(-1.2098,-0.9081)	<.0001	-0.81858
Olanzapine	128.55	128.43	-0.1132	(-0.4508,0.2244)	0.5109	-0.08808
Mirtazapine	129.16	129.52	0.3546	(0.2638,0.4454)	<.0001	0.27453
Prazosin	130.34	129.62	-0.7168	(-0.7835,-0.65)	<.0001	-0.54992
Tricyclics	128.93	128.93	0.001999	(-0.1295,0.1335)	0.9762	0.00155
Amitriptyline	128.92	128.89	-0.0334	(-0.1681,0.1013)	0.6268	-0.02591
Imipramine	129.06	129.72	0.6662	(0.0682,1.2643)	0.029	0.51623

Propensity Score Weighted Changes in Systolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	129.24	128.68	-0.5602	(-0.6395,-0.4809)	<.0001	-0.43345
Quetiapine	129.22	128.81	-0.4111	(-0.5088,-0.3134)	<.0001	-0.31813
Risperidone	129.32	128.32	-1.0005	(-1.1508,-0.8501)	<.0001	-0.7736
Olanzapine	128.51	128.38	-0.1239	(-0.4617,0.2139)	0.4721	-0.09641
Mirtazapine	128.97	129.33	0.36	(0.2703,0.4497)	<.0001	0.27912
Prazosin	130.43	129.68	-0.7505	(-0.8175,-0.6834)	<.0001	-0.57539
Tricyclics	129.27	129.24	-0.02709	(-0.1612,0.1071)	0.6923	-0.02096
Amitriptyline	129.25	129.19	-0.05551	(-0.1929,0.0819)	0.4286	-0.04295
Imipramine	129.61	130.07	0.4539	(-0.1537,1.0615)	0.143	0.35017

Number of Windows for Systolic Blood Pressure

Medication Group	n(pre)	n(post)
Antipsychotics	68676	68174
Quetiapine	45637	45344
Risperidone	18966	18816
Olanzapine	4073	4014
Mirtazapine	53167	52629
Prazosin	96796	95525
Tricyclics	21659	21466
Amitriptyline	20588	20393
Imipramine	1071	1073

Unweighted Changes in Diastolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	78.2999	78.0731	-0.2269	(-0.2805,-0.1733)	<.0001	-0.28975
Quetiapine	78.4743	78.3771	-0.09722	(-0.1634,-0.031)	0.004	-0.12388
Risperidone	78.0581	77.4717	-0.5864	(-0.6883,-0.4846)	<.0001	-0.75128
Olanzapine	77.5787	77.6047	0.02601	(-0.1954,0.2474)	0.8179	0.03353
Mirtazapine	77.9313	78.0697	0.1384	(0.0781,0.1986)	<.0001	0.17756
Prazosin	79.0076	78.4276	-0.5799	(-0.6252,-0.5346)	<.0001	-0.73399
Tricyclics	77.945	78.3426	0.3976	(0.3085,0.4867)	<.0001	0.51011
Amitriptyline	77.968	78.3426	0.3746	(0.2834,0.4659)	<.0001	0.48047
Imipramine	77.5381	78.3752	0.8371	(0.4305,1.2437)	<.0001	1.07961

Propensity Score Weighted Changes in Diastolic Blood Pressure

Medication Group	Pre-Index Year	Post-Index Year	Absolute Change (post minus pre)	95%CI	P-value	Percent Change (post minus pre)
Antipsychotics	78.1967	77.9744	-0.2224	(-0.2757,-0.169)	<.0001	-0.28436
Quetiapine	78.3593	78.2731	-0.08621	(-0.1521,-0.0203)	0.0103	-0.11001
Risperidone	77.9788	77.3963	-0.5825	(-0.6838,-0.4811)	<.0001	-0.74697
Olanzapine	77.5345	77.507	-0.02749	(-0.2482,0.1932)	0.8071	-0.03545
Mirtazapine	78.1577	78.3276	0.1699	(0.1096,0.2302)	<.0001	0.2174
Prazosin	78.9289	78.3324	-0.5965	(-0.6417,-0.5513)	<.0001	-0.75575
Tricyclics	78.1578	78.5859	0.4282	(0.3365,0.5198)	<.0001	0.54781
Amitriptyline	78.1865	78.6013	0.4148	(0.321,0.5086)	<.0001	0.53055
Imipramine	77.665	78.3324	0.6674	(0.244,1.0908)	0.002	0.8593

Number of Windows for Diastolic Blood Pressure

Medication Group	n(pre)	n(post)
Antipsychotics	68676	68174
Quetiapine	45637	45344
Risperidone	18966	18816
Olanzapine	4073	4014
Mirtazapine	53167	52629
Prazosin	96796	95525
Tricyclics	21659	21466
Amitriptyline	20588	20393
Imipramine	1071	1073

Tables - Post-Index Outcomes

Unweighted New Diagnoses of Cardiovascular Risk Factors (per 100 person years) by Augmenting Medication Group

Medication Group	Antipsychotics	Mirtazapine	Prazosin	Tricyclics
	Count per 100 person years	Count per 100 person years	Count per 100 person years	Count per 100 person years
Diabetes	4.1094	3.9223	3.327	4.2273
Dyslipidemia	17.5746	15.6917	13.7946	16.4871
Hypertension	12.9655	12.254	9.8514	12.304
Obesity	9.3303	8.5675	9.0563	9.9384

Propensity Score Weighted New Diagnoses of Cardiovascular Risk Factors (per 100 person years) by Augmenting Medication Group

Medication Group	Antipsychotics	Mirtazapine	Prazosin	Tricyclics
	Count per 100 person years	Count per 100 person years	Count per 100 person years	Count per 100 person years
Diabetes	4.0067	3.798	3.4589	4.1703
Dyslipidemia	17.0998	15.3312	14.311	16.5598
Hypertension	12.3507	11.6907	10.4689	12.4475
Obesity	9.2883	8.7688	9.0992	9.2157

New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group

Medication Group	prescribed new medication	with dose increase	with new medication or dose increase
	% (N)	% (N)	% (N)
Prazosin N=100269	7.502(7522)	3.623(3633)	9.188(9213)
Antipsychotics N=70900	7.504(5320)	3.667(2600)	9.193(6518)
Mirtazapine N=54672	8.236(4503)	4.176(2283)	10.02(5478)
Tricyclics N=21984	9.866(2169)	5.04(1108)	12.118(2664)

New Prescription or Dose Increase of a Cholesterol Medication by Augmenting Medication Group

Medication Group	prescribed new medication	with dose increase	with new medication or dose increase
	% (N)	% (N)	% (N)
Prazosin N=100269	15.351(15392)	8.353(8375)	20.829(20885)
Antipsychotics N=70900	17.257(12235)	9.238(6550)	22.904(16239)
Mirtazapine N=54672	16.508(9025)	9.4(5139)	22.538(12322)
Tricyclics N=21984	17.918(3939)	10.107(2222)	24.245(5330)

New Prescription or Dose/Potency Increase of a Statin by Augmenting Medication Group

Medication Group	prescribed new medication	with dose/potency increase	with new medication or dose/potency increase
	% (N)	% (N)	% (N)
Prazosin N=100269	12.247(12280)	7.541(7561)	17.715(17763)
Antipsychotics N=70900	13.379(9486)	8.309(5891)	19.135(13567)
Mirtazapine N=54672	12.762(6977)	8.478(4635)	18.889(10327)
Tricyclics N=21984	13.533(2975)	8.966(1971)	20.042(4406)

New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group

Medication Group	prescribed new medication	with dose increase	with new medication or dose increase
	% (N)	% (N)	% (N)
Prazosin N=100269	11.02(11050)	21.761(21820)	29.725(29805)
Antipsychotics N=70900	11.722(8311)	23.364(16565)	31.567(22381)
Mirtazapine N=54672	11.51(6293)	24.621(13461)	32.611(17829)
Tricyclics N=21984	11.718(2576)	26.465(5818)	34.612(7609)

Models - Change in Outcomes

For all subsequent model tables:

Model 0: Unadjusted

Model 1: Adjusted for sociodemographics, comorbidities, prescribing facility factors, service utilization factors

Model 2: Adding days on index medication

Model 3: Model 1 covariates + days on index med + other augmenting classes

Model 4: Model 1 covariates + days on index med + other augmenting classes + dose of augmenting med

Model 5: Propensity weighted

Model 6: Propensity weighted + days on index med

Model 7: Propensity weighted + days on index med + other augmenting classes

Model 8: Propensity weighted + days on index med + other augmenting classes + dose of augmenting med

Unadjusted and Adjusted Models for Change in Weight by Augmenting Medication Group

Weight	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.7087	(0.5918,0.8255)	<.0001	0.7105	(0.5936,0.8274)	<.0001	0.7112	(0.5944,0.828)	<.0001
Mirtazapine	1.5006	(1.3741,1.627)	<.0001	1.5002	(1.3737,1.6267)	<.0001	1.5007	(1.3743,1.6271)	<.0001
Tricyclics	0.3739	(0.1989,0.5488)	<.0001	0.3723	(0.1973,0.5474)	<.0001	0.3724	(0.1975,0.5472)	<.0001
Weight	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.7103	(0.5934,0.8271)	<.0001	0.7103	(0.5935,0.8272)	<.0001	0.6308	(0.4943,0.7673)	<.0001
Mirtazapine	1.5004	(1.374,1.6269)	<.0001	1.5004	(1.374,1.6269)	<.0001	1.6924	(1.5556,1.8291)	<.0001
Tricyclics	0.3719	(0.197,0.5468)	<.0001	0.3719	(0.197,0.5468)	<.0001	0.4468	(0.3101,0.5834)	<.0001
Weight	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.632	(0.4957,0.7683)	<.0001	0.6309	(0.4946,0.7672)	<.0001	0.631	(0.4946,0.7673)	<.0001
Mirtazapine	1.6928	(1.5562,1.8294)	<.0001	1.6926	(1.556,1.8291)	<.0001	1.6925	(1.5559,1.8291)	<.0001
Tricyclics	0.4469	(0.3104,0.5834)	<.0001	0.4464	(0.3099,0.5829)	<.0001	0.4464	(0.3099,0.5829)	<.0001

Unadjusted and Adjusted Models for Change in A1C by Augmenting Medication Group

A1C	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.0269	(0.014,0.0398)	<.0001	0.0338	(0.0209,0.0466)	<.0001	0.0338	(0.0209,0.0466)	<.0001
Mirtazapine	0.1138	(0.0998,0.1277)	<.0001	0.114	(0.1001,0.128)	<.0001	0.114	(0.1001,0.128)	<.0001
Tricyclics	0.0566	(0.0376,0.0757)	<.0001	0.0569	(0.0379,0.0759)	<.0001	0.0569	(0.0379,0.0759)	<.0001
A1C	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.0336	(0.0208,0.0465)	<.0001	0.0337	(0.0208,0.0466)	<.0001	0.0273	(0.0123,0.0422)	0.0003
Mirtazapine	0.1139	(0.0999,0.1278)	<.0001	0.1139	(0.1,0.1278)	<.0001	0.1151	(0.0999,0.1302)	<.0001
Tricyclics	0.0568	(0.0378,0.0758)	<.0001	0.0568	(0.0378,0.0758)	<.0001	0.0647	(0.0497,0.0797)	<.0001
A1C	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.0276	(0.0127,0.0425)	0.0003	0.0271	(0.0121,0.042)	0.0004	0.0270	(0.0121,0.0419)	0.0004
Mirtazapine	0.1151	(0.1,0.1303)	<.0001	0.1147	(0.0995,0.1298)	<.0001	0.1147	(0.0995,0.1298)	<.0001
Tricyclics	0.0647	(0.0497,0.0797)	<.0001	0.0644	(0.0494,0.0794)	<.0001	0.0644	(0.0494,0.0794)	<.0001

Unadjusted and Adjusted Models for Change in Glucose by Augmenting Medication Group

Glucose	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.4455	(0.0487,0.8424)	0.0278	0.5444	(0.1475,0.9412)	0.0072	0.5445	(0.1476,0.9413)	0.0072
Mirtazapine	1.8504	(1.4219,2.2788)	<.0001	1.8625	(1.4341,2.291)	<.0001	1.8627	(1.4343,2.2912)	<.0001
Tricyclics	0.6359	(0.0444,1.2274)	0.0351	0.6173	(0.0257,1.209)	0.0409	0.6176	(0.0259,1.2092)	0.0408
Glucose	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.5432	(0.1464,0.9401)	0.0073	0.5448	(0.1479,0.9416)	0.0071	0.5188	(0.0622,0.9754)	0.0259
Mirtazapine	1.8621	(1.4336,2.2906)	<.0001	1.8603	(1.4318,2.2888)	<.0001	1.8098	(1.3516,2.2681)	<.0001
Tricyclics	0.6164	(0.0247,1.2081)	0.0412	0.6154	(0.0237,1.2071)	0.0415	0.4969	(0.0381,0.9557)	0.0338
Glucose	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.524	(0.0675,0.9806)	0.0245	0.5224	(0.0658,0.9791)	0.0249	0.5221	(0.0655,0.9787)	0.025
Mirtazapine	1.8163	(1.3581,2.2745)	<.0001	1.8172	(1.3589,2.2755)	<.0001	1.8176	(1.3594,2.2759)	<.0001
Tricyclics	0.5048	(0.0461,0.9635)	0.031	0.5023	(0.0434,0.9611)	0.0319	0.5026	(0.0438,0.9615)	0.0318

Unadjusted and Adjusted Models for Change in Triglycerides by Augmenting Medication Group

Triglycerides	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	8.3806	(7.0265,9.7348)	<.0001	8.4406	(7.0873,9.794)	<.0001	8.4566	(7.1033,9.81)	<.0001
Mirtazapine	12.2771	(10.8114,13.7428)	<.0001	12.2568	(10.792,13.7216)	<.0001	12.2675	(10.8028,13.7322)	<.0001
Tricyclics	4.9363	(2.8994,6.9733)	<.0001	4.9742	(2.9385,7.0099)	<.0001	4.99	(2.9543,7.0256)	<.0001
Triglycerides	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	8.4721	(7.1188,9.8254)	<.0001	8.4788	(7.1255,9.8321)	<.0001	8.3546	(6.8011,9.908)	<.0001
Mirtazapine	12.275	(10.8104,13.7397)	<.0001	12.2666	(10.802,13.7313)	<.0001	12.8251	(11.2617,14.3886)	<.0001
Tricyclics	5.0061	(2.9705,7.0416)	<.0001	5.0021	(2.9665,7.0376)	<.0001	5.5008	(3.9335,7.0681)	<.0001
Triglycerides	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	8.3827	(6.8292,9.9361)	<.0001	8.4008	(6.8474,9.9542)	<.0001	8.4063	(6.8529,9.9597)	<.0001
Mirtazapine	12.8384	(11.2749,14.4018)	<.0001	12.8443	(11.2809,14.4076)	<.0001	12.8345	(11.2711,14.3979)	<.0001
Tricyclics	5.5255	(3.9582,7.0928)	<.0001	5.5471	(3.9799,7.1143)	<.0001	5.5412	(3.974,7.1084)	<.0001

Unadjusted and Adjusted Models for Change in HDL Cholesterol by Augmenting Medication Group

HDL	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.3558	(-0.4607,-0.251)	<.0001	-0.3636	(-0.4685,-0.2587)	<.0001	-0.3645	(-0.4694,-0.2596)	<.0001
Mirtazapine	-0.5478	(-0.6613,-0.4342)	<.0001	-0.5455	(-0.6591,-0.4319)	<.0001	-0.5459	(-0.6595,-0.4322)	<.0001
Tricyclics	-0.0442	(-0.2016,0.1132)	0.5822	-0.0398	(-0.1974,0.1178)	0.6204	-0.04033	(-0.1979,0.1172)	0.6159
HDL	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.365	(-0.4699,-0.2601)	<.0001	-0.3653	(-0.4702,-0.2603)	<.0001	-0.3098	(-0.4308,-0.1888)	<.0001
Mirtazapine	-0.5463	(-0.6599,-0.4326)	<.0001	-0.546	(-0.6596,-0.4323)	<.0001	-0.5576	(-0.6795,-0.4357)	<.0001
Tricyclics	-0.04043	(-0.198,0.1171)	0.615	-0.04029	(-0.1979,0.1173)	0.6163	-0.0969	(-0.219,0.0252)	0.1197
HDL	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.3114	(-0.4324,-0.1904)	<.0001	-0.3119	(-0.433,-0.1909)	<.0001	-0.3122	(-0.4332,-0.1912)	<.0001
Mirtazapine	-0.5581	(-0.6801,-0.4362)	<.0001	-0.5583	(-0.6802,-0.4363)	<.0001	-0.5579	(-0.6798,-0.436)	<.0001
Tricyclics	-0.09791	(-0.22,0.0242)	0.116	-0.09788	(-0.22,0.0242)	0.1161	-0.09761	(-0.2197,0.0245)	0.1171

Unadjusted and Adjusted Models for Change in LDL Cholesterol by Augmenting Medication Group

LDL	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.9614	(0.6341,1.2887)	<.0001	0.8527	(0.5264,1.1791)	<.0001	0.8487	(0.5223,1.1751)	<.0001
Mirtazapine	1.3684	(1.0142,1.7225)	<.0001	1.341	(0.9879,1.6941)	<.0001	1.3381	(0.985,1.6913)	<.0001
Tricyclics	0.2277	(-0.2648,0.7202)	0.3649	0.2821	(-0.209,0.7732)	0.2602	0.2785	(-0.2126,0.7696)	0.2664
LDL	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.8479	(0.5215,1.1743)	<.0001	0.8486	(0.5222,1.1749)	<.0001	0.9905	(0.6145,1.3666)	<.0001
Mirtazapine	1.3379	(0.9848,1.691)	<.0001	1.3371	(0.984,1.6902)	<.0001	1.4486	(1.0701,1.8271)	<.0001
Tricyclics	0.2772	(-0.2139,0.7683)	0.2686	0.2769	(-0.2143,0.768)	0.2692	0.2749	(-0.1046,0.6544)	0.1557
LDL	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.9776	(0.6017,1.3536)	<.0001	0.9791	(0.6031,1.3551)	<.0001	0.9811	(0.605,1.3572)	<.0001
Mirtazapine	1.4426	(1.0641,1.821)	<.0001	1.442	(1.0635,1.8205)	<.0001	1.4388	(1.0603,1.8173)	<.0001
Tricyclics	0.2636	(-0.1159,0.643)	0.1734	0.2658	(-0.1137,0.6452)	0.1699	0.2639	(-0.1157,0.6434)	0.173

Unadjusted and Adjusted Models for Change in Total Cholesterol by Augmenting Medication Group

Total Cholesterol	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.0318	(1.6466,2.417)	<.0001	1.9184	(1.534,2.3027)	<.0001	1.9153	(1.5309,2.2997)	<.0001
Mirtazapine	2.6615	(2.2446,3.0784)	<.0001	2.6312	(2.2153,3.0471)	<.0001	2.6292	(2.2132,3.0451)	<.0001
Tricyclics	0.8393	(0.2609,1.4176)	0.0045	0.8939	(0.3168,1.4709)	0.0024	0.8909	(0.3138,1.468)	0.0025
Total Cholesterol	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.9161	(1.5317,2.3004)	<.0001	1.9171	(1.5328,2.3015)	<.0001	2.0691	(1.6255,2.5126)	<.0001
Mirtazapine	2.6303	(2.2144,3.0462)	<.0001	2.6286	(2.2127,3.0445)	<.0001	2.7825	(2.3361,3.2288)	<.0001
Tricyclics	0.8917	(0.3147,1.4688)	0.0025	0.8909	(0.3138,1.468)	0.0025	0.9107	(0.4636,1.3577)	<.0001
Total Cholesterol	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.057	(1.6135,2.5006)	<.0001	2.06	(1.6165,2.5036)	<.0001	2.0618	(1.6182,2.5054)	<.0001
Mirtazapine	2.7771	(2.3308,3.2235)	<.0001	2.7777	(2.3313,3.2241)	<.0001	2.7736	(2.3271,3.22)	<.0001
Tricyclics	0.901	(0.454,1.348)	<.0001	0.9067	(0.4597,1.3538)	<.0001	0.9041	(0.457,1.3512)	<.0001

Unadjusted and Adjusted Models for Change in Systolic Blood Pressure by Augmenting Medication Group

Systolic	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.1041	(0.0008,0.2074)	0.0482	0.1093	(0.0061,0.2125)	0.038	0.1091	(0.0058,0.2123)	0.0384
Mirtazapine	1.0716	(0.9598,1.1834)	<.0001	1.0727	(0.961,1.1844)	<.0001	1.0726	(0.9608,1.1843)	<.0001
Tricyclics	0.7193	(0.5641,0.8745)	<.0001	0.7214	(0.5663,0.8766)	<.0001	0.7209	(0.5657,0.8761)	<.0001
Systolic	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.1083	(0.005,0.2115)	0.0398	0.1084	(0.0052,0.2117)	0.0395	0.1906	(0.0725,0.3087)	0.0016
Mirtazapine	1.0721	(0.9603,1.1838)	<.0001	1.0719	(0.9601,1.1836)	<.0001	1.1109	(0.9927,1.2291)	<.0001
Tricyclics	0.7205	(0.5653,0.8757)	<.0001	0.7206	(0.5654,0.8758)	<.0001	0.7239	(0.6056,0.8422)	<.0001
Systolic	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.1905	(0.0724,0.3086)	0.0016	0.19	(0.0719,0.3081)	0.0016	0.1901	(0.072,0.3082)	0.0016
Mirtazapine	1.1109	(0.9927,1.2291)	<.0001	1.1105	(0.9923,1.2288)	<.0001	1.1104	(0.9922,1.2286)	<.0001
Tricyclics	0.7238	(0.6055,0.8421)	<.0001	0.7234	(0.6051,0.8417)	<.0001	0.7234	(0.6051,0.8417)	<.0001

Unadjusted and Adjusted Models for Change in Diastolic Blood Pressure by Augmenting Medication Group

Diastolic	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.3532	(0.2836,0.4229)	<.0001	0.3491	(0.2794,0.4188)	<.0001	0.349	(0.2793,0.4187)	<.0001
Mirtazapine	0.7185	(0.6431,0.7939)	<.0001	0.7167	(0.6413,0.7922)	<.0001	0.7167	(0.6413,0.7922)	<.0001
Tricyclics	0.9777	(0.8731,1.0824)	<.0001	0.9727	(0.868,1.0775)	<.0001	0.9727	(0.8679,1.0774)	<.0001
Diastolic	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.3488	(0.2791,0.4185)	<.0001	0.349	(0.2793,0.4187)	<.0001	0.3742	(0.2944,0.4539)	<.0001
Mirtazapine	0.7167	(0.6413,0.7922)	<.0001	0.7165	(0.6411,0.792)	<.0001	0.7666	(0.6868,0.8464)	<.0001
Tricyclics	0.9727	(0.868,1.0775)	<.0001	0.9729	(0.8681,1.0776)	<.0001	1.0248	(0.9449,1.1047)	<.0001
Diastolic	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.3738	(0.2941,0.4536)	<.0001	0.3736	(0.2938,0.4534)	<.0001	0.3738	(0.294,0.4537)	<.0001
Mirtazapine	0.7665	(0.6866,0.8463)	<.0001	0.7666	(0.6867,0.8465)	<.0001	0.7661	(0.6863,0.846)	<.0001
Tricyclics	1.0243	(0.9444,1.1042)	<.0001	1.0243	(0.9444,1.1043)	<.0001	1.0244	(0.9445,1.1044)	<.0001

Models - Post-Index Outcomes

For all subsequent model tables:

Model 0: Unadjusted

Model 1: Adjusted for sociodemographics, comorbidities, prescribing facility factors, service utilization factors

Model 2: Adding days on index medication

Model 3: Model 1 covariates + days on index med + other augmenting classes

Model 4: Model 1 covariates + days on index med + other augmenting classes + dose of augmenting med

Model 5: Propensity weighted

Model 6: Propensity weighted + days on index med

Model 7: Propensity weighted + days on index med + other augmenting classes

Model 8: Propensity weighted + days on index med + other augmenting classes + dose of augmenting med

Difference in Incident Diagnoses of Diabetes per 100 Person Years (Reference Group Prazosin)

Dx Diabetes	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.78232	(0.5768, 0.9879)	<.0001	0.57416	(0.4122, 0.7361)	<.0001	0.53406	(0.372, 0.6961)	<.0001
Mirtazapine	0.59524	(0.374, 0.8165)	<.0001	0.24741	(0.0777, 0.4171)	0.0043	0.27551	(0.1042, 0.4469)	0.0016
Tricyclics	0.9003	(0.5838, 1.2168)	<.0001	0.8035	(0.5483, 1.0587)	<.0001	0.85391	(0.5957, 1.1121)	<.0001
Dx Diabetes	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.68857	(0.5131, 0.864)	<.0001	0.72168	(0.5419, 0.9015)	<.0001	0.54785	(0.3062, 0.7895)	<.0001
Mirtazapine	0.30329	(0.126, 0.4806)	0.0008	0.02659	(-0.182, 0.2352)	0.8027	0.33917	(0.1011, 0.5772)	0.0052
Tricyclics	0.96027	(0.6987, 1.2219)	<.0001	0.99911	(0.7312, 1.2671)	<.0001	0.71142	(0.4642, 0.9587)	<.0001
Dx Diabetes	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.4377	(0.2003, 0.6751)	0.0003	0.69381	(0.4448, 0.9428)	<.0001	0.71381	(0.4614, 0.9662)	<.0001
Mirtazapine	0.41484	(0.1759, 0.6537)	0.0007	0.58749	(0.3425, 0.8325)	<.0001	0.35823	(0.0737, 0.6428)	0.0136
Tricyclics	0.81997	(0.5707, 1.0692)	<.0001	1.04032	(0.7865, 1.2941)	<.0001	1.06677	(0.8094, 1.3241)	<.0001

Difference in Incident Diagnoses of Dyslipidemia per 100 Person Years (Reference Group Prazosin)

Dx Dyslipidemia	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	3.78002	(3.255, 4.3051)	<.0001	2.69189	(2.2734, 3.1103)	<.0001	2.5508	(2.1326, 2.969)	<.0001
Mirtazapine	1.89711	(1.3249, 2.4693)	<.0001	0.90596	(0.4575, 1.3544)	<.0001	1.03752	(0.5851, 1.4899)	<.0001
Tricyclics	2.69256	(1.8891, 3.496)	<.0001	2.35698	(1.705, 3.009)	<.0001	2.52597	(1.8681, 3.1838)	<.0001
Dx Dyslipidemia	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	3.17103	(2.7102, 3.6318)	<.0001	3.26058	(2.7928, 3.7283)	<.0001	2.78877	(2.1685, 3.409)	<.0001
Mirtazapine	1.08691	(0.6151, 1.5587)	<.0001	0.34253	(-0.2163, 0.9014)	0.2296	1.02025	(0.4114, 1.6291)	0.001
Tricyclics	2.77051	(2.1028, 3.4382)	<.0001	2.84783	(2.1705, 3.5252)	<.0001	2.24882	(1.6246, 2.8731)	<.0001
Dx Dyslipidemia	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.45187	(1.8377, 3.066)	<.0001	3.55909	(2.909, 4.2091)	<.0001	3.61969	(2.9644, 4.2749)	<.0001
Mirtazapine	1.34422	(0.7314, 1.9571)	<.0001	1.93148	(1.3012, 2.5618)	<.0001	1.2731	(0.5357, 2.0105)	0.0007
Tricyclics	2.64748	(2.0177, 3.2772)	<.0001	3.32333	(2.6823, 3.9644)	<.0001	3.38474	(2.7385, 4.031)	<.0001

Difference in Incident Diagnoses of Hypertension per 100 Person Years (Reference Group Prazosin)

Dx Hypertension	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	3.11412	(2.6619, 3.5663)	<.0001	2.01865	(1.6744, 2.363)	<.0001	1.93191	(1.587, 2.2768)	<.0001
Mirtazapine	2.40255	(1.9083, 2.8968)	<.0001	1.06434	(0.6968, 1.4319)	<.0001	1.11472	(0.7448, 1.4847)	<.0001
Tricyclics	2.45263	(1.7709, 3.1344)	<.0001	2.02432	(1.4902, 2.5585)	<.0001	2.10288	(1.5648, 2.641)	<.0001
Dx Hypertension	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.43347	(2.0555, 2.8115)	<.0001	2.53119	(2.1443, 2.9181)	<.0001	1.88179	(1.3466, 2.417)	<.0001
Mirtazapine	1.24726	(0.8615, 1.633)	<.0001	0.39082	(-0.0637, 0.8454)	0.092	1.2218	(0.6931, 1.7505)	<.0001
Tricyclics	2.32516	(1.7809, 2.8695)	<.0001	2.40913	(1.8524, 2.9658)	<.0001	1.97858	(1.438, 2.5191)	<.0001
Dx Hypertension	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.60279	(1.0726, 2.1329)	<.0001	2.77899	(2.2204, 3.3376)	<.0001	2.84942	(2.2834, 3.4154)	<.0001
Mirtazapine	1.41086	(0.879, 1.9428)	<.0001	2.15681	(1.613, 2.7006)	<.0001	1.35576	(0.7222, 1.9894)	<.0001
Tricyclics	2.21379	(1.6689, 2.7586)	<.0001	2.93772	(2.3884, 3.4871)	<.0001	3.01319	(2.4565, 3.5699)	<.0001

Difference in Incident Diagnoses of Obesity per 100 Person Years (Reference Group Prazosin)

Dx Obesity	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.274	(-0.0555, 0.6035)	0.1032	0.41365	(0.0612, 0.7661)	0.0214	0.25016	(-0.1021, 0.6025)	0.164
Mirtazapine	-0.48876	(-0.8387, -0.1388)	0.0062	-0.36401	(-0.7402, 0.0122)	0.0579	-0.25604	(-0.636, 0.1239)	0.1865
Tricyclics	0.88208	(0.3696, 1.3946)	0.0007	0.66099	(0.1205, 1.2015)	0.0165	0.80804	(0.2618, 1.3543)	0.0037
Dx Obesity	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.29901	(-0.0888, 0.6868)	0.1307	0.34324	(-0.0525, 0.7389)	0.0891	0.18908	(-0.1958, 0.5739)	0.3356
Mirtazapine	-0.53822	(-0.9391, -0.1373)	0.0085	-1.31615	(-1.7925, -0.8398)	<.0001	-0.33044	(-0.7081, 0.0472)	0.0864
Tricyclics	0.75294	(0.1933, 1.3126)	0.0084	0.80595	(0.2352, 1.3767)	0.0056	0.11644	(-0.272, 0.5049)	0.5568
Dx Obesity	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.04945	(-0.3333, 0.4322)	0.8001	0.09704	(-0.3099, 0.5039)	0.6402	0.13125	(-0.2823, 0.5447)	0.5339
Mirtazapine	-0.24178	(-0.621, 0.1374)	0.2114	-0.48348	(-0.8764, -0.0905)	0.0159	-1.14537	(-1.6033, -0.6875)	<.0001
Tricyclics	0.24617	(-0.1449, 0.6372)	0.2173	0.19784	(-0.205, 0.6007)	0.3358	0.23863	(-0.1709, 0.6482)	0.2534

Comparison of New Prescription or Dose Increase of a Diabetes Medication (Reference Group Prazosin)

Rx Diabetes	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.00495	(-0.2729, 0.2828)	0.9722	-0.20837	(-0.4359, 0.0192)	0.0727	-0.23727	(-0.4651, -0.0094)	0.0412
Mirtazapine	0.83147	(0.5261, 1.1368)	<.0001	-0.28044	(-0.5213, -0.0396)	0.0225	-0.25646	(-0.4983, -0.0146)	0.0376
Tricyclics	2.92962	(2.4959, 3.3633)	<.0001	1.61833	(1.269, 1.9677)	<.0001	1.65808	(1.3072, 2.0089)	<.0001
Rx Diabetes	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.2434	(-0.4854, -0.0014)	0.0486	-0.20063	(-0.4486, 0.0474)	0.1128	-0.05546	(-0.3822, 0.2713)	0.7394
Mirtazapine	-0.31932	(-0.5717, -0.0669)	0.0132	-1.05928	(-1.3591, -0.7594)	<.0001	-0.06015	(-0.3869, 0.2666)	0.7182
Tricyclics	1.72709	(1.3693, 2.0849)	<.0001	1.81359	(1.4473, 2.1799)	<.0001	1.0522	(0.7158, 1.3886)	<.0001
Rx Diabetes	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	-0.20609	(-0.5303, 0.1181)	0.2127	0.14975	(-0.1852, 0.4847)	0.381	0.14642	(-0.1884, 0.4813)	0.3914
Mirtazapine	0.07445	(-0.2537, 0.4026)	0.6566	0.51844	(0.1803, 0.8566)	0.0027	0.57288	(0.1684, 0.9773)	0.0055
Tricyclics	1.23389	(0.8951, 1.5726)	<.0001	1.82775	(1.4806, 2.1749)	<.0001	1.82236	(1.4753, 2.1694)	<.0001

Comparison of New Prescription or Dose Increase of a Cholesterol Medication (Reference Group Prazosin)

Rx Cholesterol	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.07512	(1.6786, 2.4716)	<.0001	1.66789	(1.3167, 2.0191)	<.0001	1.61676	(1.2649, 1.9686)	<.0001
Mirtazapine	1.70907	(1.2814, 2.1368)	<.0001	0.50218	(0.1296, 0.8747)	0.0082	0.54722	(0.1735, 0.921)	0.0041
Tricyclics	3.41594	(2.8162, 4.0157)	<.0001	2.81036	(2.2762, 3.3446)	<.0001	2.87169	(2.3359, 3.4075)	<.0001
Rx Cholesterol	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	2.07932	(1.6994, 2.4593)	<.0001	2.18159	(1.7961, 2.5671)	<.0001	1.71413	(1.2523, 2.1759)	<.0001
Mirtazapine	0.70333	(0.3105, 1.0962)	0.0004	-0.51937	(-0.9905, -0.0483)	0.0307	0.63504	(0.1774, 1.0927)	0.0065
Tricyclics	3.17663	(2.6317, 3.7216)	<.0001	3.28422	(2.7318, 3.8366)	<.0001	1.892	(1.4278, 2.3562)	<.0001
Rx Cholesterol	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.50511	(1.0443, 1.966)	<.0001	2.32466	(1.8408, 2.8086)	<.0001	2.36067	(1.8747, 2.8466)	<.0001
Mirtazapine	0.82824	(0.3688, 1.2877)	0.0004	1.48302	(1.0063, 1.9598)	<.0001	1.00225	(0.437, 1.5675)	0.0005
Tricyclics	2.14076	(1.674, 2.6075)	<.0001	2.88086	(2.4027, 3.359)	<.0001	2.91904	(2.4389, 3.3992)	<.0001

Comparison of New Prescription or Dose/Potency Increase of a Statin (Reference Group Prazosin)

Rx Statin	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.42006	(1.0481, 1.792)	<.0001	1.11153	(0.774, 1.449)	<.0001	1.08916	(0.751, 1.4273)	<.0001
Mirtazapine	1.17367	(0.7722, 1.5752)	<.0001	0.12894	(-0.229, 0.4868)	0.4801	0.14836	(-0.2104, 0.5071)	0.4176
Tricyclics	2.3265	(1.7637, 2.8893)	<.0001	1.96414	(1.4509, 2.4774)	<.0001	1.99078	(1.4765, 2.5051)	<.0001
Rx Statin	Model 3			Model4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.35612	(0.9916, 1.7207)	<.0001	1.44093	(1.0708, 1.8111)	<.0001	1.13477	(0.7014, 1.5681)	<.0001
Mirtazapine	0.23288	(-0.1445, 0.6103)	0.2265	-0.84191	(-1.2943, -0.3895)	0.0003	0.21689	(-0.2123, 0.6461)	0.3219
Tricyclics	2.16509	(1.642, 2.6882)	<.0001	2.25283	(1.7222, 2.7835)	<.0001	1.17665	(0.7415, 1.6118)	<.0001
Rx Statin	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.98463	(0.5521, 1.4172)	<.0001	1.55136	(1.0974, 2.0053)	<.0001	1.58415	(1.128, 2.0403)	<.0001
Mirtazapine	0.3554	(-0.0753, 0.7861)	0.1058	0.86583	(0.4184, 1.3133)	0.0001	0.41573	(-0.1145, 0.946)	0.1244
Tricyclics	1.35462	(0.9172, 1.792)	<.0001	1.88987	(1.4417, 2.338)	<.0001	1.92429	(1.4739, 2.3747)	<.0001

Comparison of New Prescription or Dose Increase of a Blood Pressure Medication (Reference Group Prazosin)

Rx Blood Pressure	Model 0			Model 1			Model 2		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.84196	(1.3992, 2.2848)	<.0001	1.29574	(0.8695, 1.722)	<.0001	1.22614	(0.7991, 1.6532)	<.0001
Mirtazapine	2.8858	(2.4048, 3.3668)	<.0001	0.90554	(0.4475, 1.3635)	0.0001	0.96938	(0.5101, 1.4287)	<.0001
Tricyclics	4.8865	(4.213, 5.56)	<.0001	3.64591	(2.9949, 4.297)	<.0001	3.7283	(3.0756, 4.381)	<.0001
Rx Blood Pressure	Model 3			Model 4			Model 5		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	1.37182	(0.9101, 1.8335)	<.0001	1.50049	(1.033, 1.968)	<.0001	1.15181	(0.6372, 1.6664)	<.0001
Mirtazapine	0.97863	(0.4925, 1.4648)	<.0001	-1.01628	(-1.6009, -0.4316)	0.0007	0.94311	(0.429, 1.4572)	0.0003
Tricyclics	3.86537	(3.1996, 4.5311)	<.0001	4.01046	(3.3372, 4.6837)	<.0001	3.0258	(2.505, 3.5466)	<.0001
Rx Blood Pressure	Model 6			Model 7			Model 8		
	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val	Diff to Ref	95% CI	p-val
Antipsychotics	0.90614	(0.3918, 1.4205)	0.0006	1.63279	(1.0924, 2.1731)	<.0001	1.68865	(1.146, 2.2313)	<.0001
Mirtazapine	1.18388	(0.668, 1.6998)	<.0001	2.02681	(1.4885, 2.5651)	<.0001	1.14411	(0.5053, 1.7829)	0.0004
Tricyclics	3.33473	(2.8115, 3.858)	<.0001	4.10078	(3.5633, 4.6382)	<.0001	4.16565	(3.626, 4.7053)	<.0001

Myocardial Infarction Hazard Ratio (reference group Prazosin)

MI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.304	(1.2143,1.4012)	<.0001	1.174	(1.0924,1.2614)	<.0001	1.182	(1.0999,1.2703)	<.0001
Mirtazapine	1.693	(1.5758,1.818)	<.0001	1.31	(1.2186,1.408)	<.0001	1.302	(1.2114,1.3999)	<.0001
Tricyclics	1.392	(1.257,1.5408)	<.0001	1.204	(1.0867,1.3334)	0.0004	1.195	(1.0786,1.3237)	0.0007
MI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.216	(1.1275,1.3112)	<.0001	1.217	(1.1282,1.3123)	<.0001	1.145	(1.0558,1.2411)	0.0011
Mirtazapine	1.369	(1.2693,1.4761)	<.0001	1.357	(1.2391,1.4871)	<.0001	1.283	(1.1855,1.3879)	<.0001
Tricyclics	1.252	(1.1285,1.3886)	<.0001	1.253	(1.1291,1.3894)	<.0001	1.062	(0.978,1.1534)	0.1525
MI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.156	(1.0662,1.2537)	0.0004	1.205	(1.1084,1.3105)	<.0001	1.206	(1.1086,1.311)	<.0001
Mirtazapine	1.285	(1.1874,1.3904)	<.0001	1.346	(1.2404,1.4598)	<.0001	1.341	(1.2177,1.4778)	<.0001
Tricyclics	1.075	(0.9896,1.1675)	0.0871	1.135	(1.0431,1.2343)	0.0033	1.135	(1.0433,1.2347)	0.0032

Coronary Artery Bypass Graft Hazard Ratio (reference group Prazosin)

CABG	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.315	(1.225,1.4109)	<.0001	1.191	(1.1092,1.2784)	<.0001	1.198	(1.116,1.2865)	<.0001
Mirtazapine	1.685	(1.5696,1.8084)	<.0001	1.301	(1.2115,1.3977)	<.0001	1.294	(1.2048,1.3902)	<.0001
Tricyclics	1.425	(1.2895,1.5742)	<.0001	1.242	(1.1234,1.3727)	<.0001	1.234	(1.1161,1.364)	<.0001
CABG	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.236	(1.1469,1.3311)	<.0001	1.235	(1.1464,1.3309)	<.0001	1.154	(1.0652,1.2497)	0.0004
Mirtazapine	1.358	(1.2605,1.4638)	<.0001	1.363	(1.2451,1.4912)	<.0001	1.274	(1.1787,1.378)	<.0001
Tricyclics	1.291	(1.1667,1.4295)	<.0001	1.291	(1.1664,1.4293)	<.0001	1.083	(0.9981,1.1742)	0.0555
CABG	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.175	(1.0849,1.2732)	<.0001	1.225	(1.1277,1.3307)	<.0001	1.224	(1.1265,1.3295)	<.0001
Mirtazapine	1.281	(1.1846,1.3852)	<.0001	1.339	(1.2355,1.452)	<.0001	1.354	(1.2307,1.4907)	<.0001
Tricyclics	1.107	(1.0203,1.2008)	0.0145	1.166	(1.0728,1.2663)	0.0003	1.165	(1.0719,1.2654)	0.0003

Percutaneous Coronary Intervention Hazard Ratio (reference group Prazosin)

PCI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.303	(1.2124,1.4013)	<.0001	1.179	(1.0959,1.2676)	<.0001	1.188	(1.1041,1.2773)	<.0001
Mirtazapine	1.716	(1.5969,1.8445)	<.0001	1.327	(1.2343,1.4277)	<.0001	1.32	(1.2269,1.4194)	<.0001
Tricyclics	1.373	(1.2378,1.5228)	<.0001	1.207	(1.0873,1.339)	0.0004	1.198	(1.0791,1.3291)	0.0007
PCI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.218	(1.1286,1.3149)	<.0001	1.22	(1.1299,1.3167)	<.0001	1.143	(1.0535,1.2407)	0.0013
Mirtazapine	1.382	(1.2804,1.4911)	<.0001	1.361	(1.2411,1.4918)	<.0001	1.296	(1.1968,1.403)	<.0001
Tricyclics	1.247	(1.1226,1.3862)	<.0001	1.249	(1.1237,1.3877)	<.0001	1.05	(0.9658,1.1417)	0.2521
PCI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.164	(1.0727,1.2636)	0.0003	1.214	(1.1151,1.3211)	<.0001	1.215	(1.1162,1.3227)	<.0001
Mirtazapine	1.302	(1.2021,1.4095)	<.0001	1.358	(1.2512,1.4749)	<.0001	1.342	(1.2172,1.4798)	<.0001
Tricyclics	1.078	(0.9909,1.1718)	0.0809	1.132	(1.0397,1.2331)	0.0043	1.133	(1.0405,1.2343)	0.0041

Heart Failure Hazard Ratio (reference group Prazosin)

HF	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.281	(1.1893,1.38)	<.0001	1.172	(1.088,1.2634)	<.0001	1.18	(1.0946,1.2714)	<.0001
Mirtazapine	1.623	(1.5064,1.7494)	<.0001	1.294	(1.1999,1.3954)	<.0001	1.287	(1.1931,1.3878)	<.0001
Tricyclics	1.402	(1.2619,1.5568)	<.0001	1.237	(1.1129,1.3744)	<.0001	1.229	(1.1056,1.3656)	0.0001
HF	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.228	(1.135,1.3282)	<.0001	1.231	(1.1377,1.3315)	<.0001	1.145	(1.0527,1.246)	0.0016
Mirtazapine	1.362	(1.2589,1.4746)	<.0001	1.32	(1.1997,1.4528)	<.0001	1.259	(1.1591,1.3671)	<.0001
Tricyclics	1.294	(1.1627,1.4401)	<.0001	1.297	(1.1651,1.4432)	<.0001	1.101	(1.0109,1.1987)	0.0271
HF	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.157	(1.0634,1.2591)	0.0007	1.216	(1.1144,1.3273)	<.0001	1.218	(1.116,1.3295)	<.0001
Mirtazapine	1.264	(1.1636,1.3727)	<.0001	1.336	(1.2262,1.4548)	<.0001	1.31	(1.1836,1.4503)	<.0001
Tricyclics	1.104	(1.0133,1.202)	0.0236	1.169	(1.0716,1.2752)	0.0004	1.171	(1.073,1.2771)	0.0004

Unstable Angina Hazard Ratio (reference group Prazosin)

Unstable Angina	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.308	(1.2185,1.4035)	<.0001	1.183	(1.1021,1.2704)	<.0001	1.192	(1.1098,1.2794)	<.0001
Mirtazapine	1.709	(1.5925,1.8336)	<.0001	1.313	(1.2223,1.4094)	<.0001	1.304	(1.2147,1.4008)	<.0001
Tricyclics	1.406	(1.2723,1.5545)	<.0001	1.226	(1.109,1.3564)	<.0001	1.218	(1.1011,1.3468)	0.0001
Unstable Angina	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.227	(1.1391,1.3222)	<.0001	1.227	(1.1391,1.3225)	<.0001	1.145	(1.0575,1.2406)	0.0009
Mirtazapine	1.366	(1.2683,1.4717)	<.0001	1.365	(1.2474,1.4929)	<.0001	1.29	(1.1932,1.3939)	<.0001
Tricyclics	1.273	(1.1492,1.4092)	<.0001	1.273	(1.1492,1.4094)	<.0001	1.066	(0.9824,1.156)	0.1257
Unstable Angina	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.168	(1.078,1.2649)	0.0001	1.217	(1.1208,1.3223)	<.0001	1.217	(1.12,1.3218)	<.0001
Mirtazapine	1.291	(1.1942,1.3953)	<.0001	1.349	(1.2448,1.4618)	<.0001	1.357	(1.2337,1.493)	<.0001
Tricyclics	1.091	(1.006,1.1843)	0.0355	1.149	(1.0573,1.2482)	0.0011	1.148	(1.0567,1.2478)	0.0011

Stroke Hazard Ratio (reference group Prazosin)

Stroke	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.291	(1.203,1.386)	<.0001	1.177	(1.0958,1.2634)	<.0001	1.185	(1.1032,1.2721)	<.0001
Mirtazapine	1.669	(1.5546,1.7911)	<.0001	1.293	(1.2037,1.3887)	<.0001	1.285	(1.1965,1.3806)	<.0001
Tricyclics	1.415	(1.281,1.5638)	<.0001	1.237	(1.1187,1.3671)	<.0001	1.228	(1.1109,1.3577)	<.0001
Stroke	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.221	(1.1335,1.316)	<.0001	1.221	(1.1333,1.3161)	<.0001	1.135	(1.0475,1.229)	0.002
Mirtazapine	1.347	(1.2504,1.4519)	<.0001	1.349	(1.232,1.476)	<.0001	1.262	(1.1676,1.3647)	<.0001
Tricyclics	1.285	(1.1607,1.4222)	<.0001	1.285	(1.1605,1.4222)	<.0001	1.074	(0.9903,1.1648)	0.0846
Stroke	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.162	(1.0724,1.2587)	0.0002	1.211	(1.1148,1.3156)	<.0001	1.21	(1.114,1.3149)	<.0001
Mirtazapine	1.271	(1.1755,1.3743)	<.0001	1.328	(1.2253,1.4397)	<.0001	1.337	(1.2151,1.472)	<.0001
Tricyclics	1.1	(1.0137,1.1928)	0.0222	1.158	(1.0661,1.2581)	0.0005	1.158	(1.0654,1.2575)	0.0005

Any Cardiovascular Event Hazard Ratio (reference group Prazosin)

Any CVD	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.242	(1.1495,1.343)	<.0001	1.149	(1.0623,1.2421)	0.0005	1.156	(1.0694,1.2506)	0.0003
Mirtazapine	1.6	(1.4804,1.7304)	<.0001	1.293	(1.1954,1.399)	<.0001	1.285	(1.1881,1.3908)	<.0001
Tricyclics	1.36	(1.2175,1.5185)	<.0001	1.213	(1.0853,1.3551)	0.0007	1.203	(1.0769,1.3449)	0.0011
Any CVD	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.206	(1.1108,1.3092)	<.0001	1.21	(1.1144,1.3137)	<.0001	1.117	(1.0225,1.2194)	0.014
Mirtazapine	1.363	(1.2554,1.4804)	<.0001	1.304	(1.1797,1.4409)	<.0001	1.243	(1.1403,1.3541)	<.0001
Tricyclics	1.275	(1.1389,1.4264)	<.0001	1.278	(1.1421,1.4306)	<.0001	1.079	(0.9874,1.1795)	0.0927
Any CVD	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.137	(1.0413,1.2421)	0.0043	1.203	(1.0983,1.3183)	<.0001	1.207	(1.1012,1.322)	<.0001
Mirtazapine	1.258	(1.1543,1.3711)	<.0001	1.332	(1.2184,1.4557)	<.0001	1.286	(1.1565,1.4297)	<.0001
Tricyclics	1.083	(0.9905,1.1836)	0.0803	1.156	(1.056,1.2661)	0.0017	1.159	(1.0584,1.2692)	0.0015

All-Cause Mortality Hazard Ratio (reference group Prazosin)

Mortality	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	2.265	(2.0858,2.4604)	<.0001	1.997	(1.8379,2.1698)	<.0001	2.082	(1.9157,2.2618)	<.0001
Mirtazapine	2.205	(2.0197,2.407)	<.0001	1.698	(1.5545,1.8552)	<.0001	1.591	(1.4567,1.7387)	<.0001
Tricyclics	1.616	(1.4236,1.834)	<.0001	1.448	(1.2752,1.6447)	<.0001	1.334	(1.1742,1.5146)	<.0001
Mortality	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	2.382	(2.1808,2.6015)	<.0001	2.413	(2.2089,2.6349)	<.0001	1.823	(1.658,2.004)	<.0001
Mirtazapine	1.718	(1.5669,1.8842)	<.0001	1.374	(1.2315,1.5325)	<.0001	1.586	(1.4389,1.7477)	<.0001
Tricyclics	1.412	(1.2414,1.6052)	<.0001	1.427	(1.2547,1.6224)	<.0001	1.392	(1.2591,1.5382)	<.0001
Mortality	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.894	(1.7226,2.0823)	<.0001	2.18	(1.9745,2.4078)	<.0001	2.212	(2.0032,2.4427)	<.0001
Mirtazapine	1.491	(1.3524,1.6431)	<.0001	1.601	(1.4481,1.771)	<.0001	1.253	(1.1143,1.4092)	0.0002
Tricyclics	1.268	(1.1469,1.4018)	<.0001	1.326	(1.1979,1.4687)	<.0001	1.344	(1.2135,1.4879)	<.0001

Tables - CVD and Mortality Sensitivity Analysis Using All Available Post-Index Data

For all subsequent model tables:

Model 0: Unadjusted

Model 1: Adjusted for sociodemographics, comorbidities, prescribing facility factors, service utilization factors

Model 2: Adding days on index medication

Model 3: Model 1 covariates + days on index med + other augmenting classes

Model 4: Model 1 covariates + days on index med + other augmenting classes + dose of augmenting med

Model 5: Propensity weighted

Model 6: Propensity weighted + days on index med

Model 7: Propensity weighted + days on index med + other augmenting classes

Model 8: Propensity weighted + days on index med + other augmenting classes + dose of augmenting med

Myocardial Infarction Hazard Ratio (reference group Prazosin)

MI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.097	(1.0165,1.1839)	0.0172	1.062	(0.9843,1.1468)	0.1201	1.07	(0.9908,1.1547)	0.0848
Mirtazapine	1.303	(1.2026,1.4121)	<.0001	1.128	(1.0401,1.2225)	0.0036	1.122	(1.0352,1.217)	0.0051
Tricyclics	1.276	(1.1491,1.417)	<.0001	1.155	(1.0393,1.2833)	0.0075	1.149	(1.0337,1.2767)	0.01
MI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.058	(0.9759,1.1474)	0.1707	1.058	(0.9757,1.1476)	0.172	0.998	(0.9152,1.0884)	0.9645
Mirtazapine	1.153	(1.0601,1.2547)	0.0009	1.154	(1.0415,1.2782)	0.0062	1.082	(0.9917,1.18)	0.0764
Tricyclics	1.164	(1.0459,1.2956)	0.0054	1.164	(1.0458,1.2957)	0.0054	1.066	(0.9786,1.1623)	0.1426
MI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.045	(0.958,1.1396)	0.322	1.021	(0.9331,1.1172)	0.6501	1.019	(0.9314,1.1155)	0.6777
Mirtazapine	1.108	(1.0155,1.2085)	0.0211	1.15	(1.0515,1.2585)	0.0022	1.172	(1.0525,1.304)	0.0038
Tricyclics	1.083	(0.9932,1.1801)	0.071	1.098	(1.0055,1.1986)	0.0372	1.096	(1.004,1.1971)	0.0405

Coronary Artery Bypass Graft Hazard Ratio (reference group Prazosin)

CABG	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.043	(0.9435,1.154)	0.4079	1.018	(0.9205,1.1265)	0.7249	1.024	(0.9256,1.133)	0.645
Mirtazapine	1.209	(1.0866,1.3452)	0.0005	1.063	(0.9544,1.183)	0.2682	1.058	(0.9506,1.1785)	0.3003
Tricyclics	1.451	(1.2735,1.6538)	<.0001	1.386	(1.2156,1.5814)	<.0001	1.38	(1.2097,1.5741)	<.0001
CABG	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.028	(0.9236,1.1437)	0.6151	1.026	(0.9221,1.1423)	0.6347	0.996	(0.8873,1.1173)	0.9412
Mirtazapine	1.07	(0.9569,1.1964)	0.2353	1.086	(0.9483,1.2449)	0.2321	1.07	(0.9529,1.201)	0.2532
Tricyclics	1.395	(1.2204,1.5943)	<.0001	1.393	(1.2189,1.5927)	<.0001	1.281	(1.1475,1.4299)	<.0001
CABG	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.032	(0.9192,1.1579)	0.5965	1.059	(0.9402,1.1937)	0.3433	1.058	(0.939,1.1927)	0.3534
Mirtazapine	1.098	(0.9777,1.2325)	0.1146	1.144	(1.0161,1.289)	0.0262	1.158	(1.005,1.3343)	0.0425
Tricyclics	1.307	(1.1705,1.4591)	<.0001	1.352	(1.2086,1.5123)	<.0001	1.351	(1.2074,1.5112)	<.0001

Percutaneous Coronary Intervention Hazard Ratio (reference group Prazosin)

PCI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.035	(0.9759,1.0974)	0.2526	1.021	(0.9624,1.0826)	0.4949	1.023	(0.9643,1.085)	0.4524
Mirtazapine	1.164	(1.0929,1.2392)	<.0001	1.036	(0.9729,1.104)	0.2682	1.035	(0.9715,1.1025)	0.2879
Tricyclics	1.242	(1.1457,1.3462)	<.0001	1.174	(1.083,1.2737)	0.0001	1.173	(1.0811,1.2717)	0.0001
PCI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.043	(0.9799,1.1104)	0.1859	1.053	(0.9887,1.1206)	0.1087	0.989	(0.9244,1.0571)	0.7362
Mirtazapine	1.059	(0.9912,1.1305)	0.0899	0.955	(0.8818,1.0352)	0.2649	1.025	(0.9578,1.0971)	0.4744
Tricyclics	1.205	(1.1095,1.308)	<.0001	1.214	(1.1182,1.3184)	<.0001	1.095	(1.0246,1.1694)	0.0073
PCI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.027	(0.9602,1.0984)	0.4374	1.048	(0.9771,1.1238)	0.19	1.057	(0.9854,1.1336)	0.1217
Mirtazapine	1.052	(0.9828,1.1258)	0.1448	1.064	(0.9924,1.1416)	0.0806	0.967	(0.8891,1.0512)	0.4286
Tricyclics	1.121	(1.0488,1.1974)	0.0007	1.146	(1.071,1.2259)	<.0001	1.154	(1.0789,1.2351)	<.0001

Heart Failure Hazard Ratio (reference group Prazosin)

HF	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.099	(1.0415,1.1593)	0.0006	1.046	(0.9911,1.1036)	0.1023	1.046	(0.9914,1.1042)	0.0996
Mirtazapine	1.427	(1.3504,1.5086)	<.0001	1.14	(1.0783,1.2058)	<.0001	1.14	(1.078,1.2055)	<.0001
Tricyclics	1.325	(1.2324,1.4248)	<.0001	1.11	(1.0321,1.1945)	0.005	1.11	(1.0318,1.1942)	0.0051
HF	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.075	(1.0158,1.1375)	0.0124	1.074	(1.0147,1.1367)	0.0137	0.958	(0.902,1.0173)	0.1615
Mirtazapine	1.159	(1.094,1.2288)	<.0001	1.17	(1.0908,1.2556)	<.0001	1.078	(1.0147,1.1442)	0.0148
Tricyclics	1.138	(1.0564,1.2251)	0.0006	1.137	(1.0554,1.2241)	0.0007	1.001	(0.9424,1.0626)	0.9829
HF	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.011	(0.952,1.074)	0.7187	1.052	(0.9886,1.1203)	0.1093	1.052	(0.9881,1.12)	0.1128
Mirtazapine	1.121	(1.0557,1.1905)	0.0002	1.137	(1.0684,1.2092)	<.0001	1.141	(1.06,1.2286)	0.0005
Tricyclics	1.014	(0.955,1.0772)	0.6445	1.043	(0.9814,1.1092)	0.1741	1.043	(0.981,1.109)	0.1785

Unstable Angina Hazard Ratio (reference group Prazosin)

Unstable Angina	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.159	(0.9794,1.3726)	0.0857	1.122	(0.947,1.3284)	0.1839	1.109	(0.9357,1.314)	0.2329
Mirtazapine	1.168	(0.97,1.4052)	0.1014	1.006	(0.835,1.2125)	0.948	1.014	(0.8414,1.2221)	0.8838
Tricyclics	1.631	(1.3143,2.0244)	<.0001	1.518	(1.2213,1.887)	0.0002	1.53	(1.2309,1.9026)	0.0001
Unstable Angina	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.107	(0.9234,1.3265)	0.2723	1.125	(0.9381,1.3481)	0.2043	1.084	(0.8931,1.3147)	0.4157
Mirtazapine	1.046	(0.8612,1.2716)	0.6476	0.841	(0.6639,1.065)	0.1505	1.008	(0.8255,1.2319)	0.9347
Tricyclics	1.603	(1.284,2.0018)	<.0001	1.629	(1.3048,2.035)	<.0001	1.352	(1.1226,1.6281)	0.0015
Unstable Angina	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.107	(0.9117,1.3432)	0.3054	1.069	(0.8742,1.308)	0.5143	1.087	(0.8882,1.3294)	0.4191
Mirtazapine	1.028	(0.8414,1.2561)	0.7867	1.078	(0.8762,1.3258)	0.4781	0.867	(0.6774,1.1094)	0.2563
Tricyclics	1.385	(1.1496,1.6684)	0.0006	1.449	(1.1975,1.7544)	0.0001	1.472	(1.216,1.7822)	<.0001

Stroke Hazard Ratio (reference group Prazosin)

Stroke	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.214	(1.0889,1.3534)	0.0005	1.162	(1.0424,1.2964)	0.0068	1.166	(1.0451,1.3004)	0.0059
Mirtazapine	1.297	(1.1534,1.459)	<.0001	1.107	(0.9836,1.2461)	0.0918	1.105	(0.9818,1.2441)	0.0978
Tricyclics	1.269	(1.0885,1.4791)	0.0023	1.175	(1.0072,1.3711)	0.0403	1.173	(1.005,1.3683)	0.0431
Stroke	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.172	(1.0441,1.3159)	0.0071	1.181	(1.0515,1.3257)	0.005	1.062	(0.9386,1.2026)	0.3379
Mirtazapine	1.085	(0.9596,1.2263)	0.1931	0.996	(0.8588,1.1561)	0.9626	1.062	(0.9354,1.2047)	0.3549
Tricyclics	1.163	(0.9948,1.3595)	0.0582	1.171	(1.0015,1.3691)	0.0479	1.057	(0.9325,1.1972)	0.388
Stroke	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.104	(0.9749,1.2498)	0.119	1.109	(0.9751,1.2618)	0.1149	1.116	(0.9808,1.2696)	0.0958
Mirtazapine	1.089	(0.9596,1.2361)	0.1863	1.077	(0.9461,1.227)	0.2608	1.006	(0.8615,1.1745)	0.9405
Tricyclics	1.083	(0.9559,1.2279)	0.2099	1.085	(0.9553,1.2322)	0.2091	1.091	(0.9606,1.2394)	0.1799

Any Cardiovascular Event Hazard Ratio (reference group Prazosin)

Any CVD	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.08	(1.0443,1.1176)	<.0001	1.049	(1.0142,1.0856)	0.0055	1.052	(1.0163,1.088)	0.0038
Mirtazapine	1.291	(1.2453,1.3378)	<.0001	1.097	(1.0586,1.1377)	<.0001	1.096	(1.0571,1.1362)	<.0001
Tricyclics	1.319	(1.26,1.3817)	<.0001	1.188	(1.1343,1.2446)	<.0001	1.186	(1.1324,1.2426)	<.0001
Any CVD	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.075	(1.0368,1.1142)	<.0001	1.079	(1.0413,1.1191)	<.0001	0.98	(0.9432,1.0188)	0.3105
Mirtazapine	1.12	(1.0784,1.1625)	<.0001	1.067	(1.0199,1.1173)	0.005	1.051	(1.0109,1.0924)	0.0122
Tricyclics	1.216	(1.1596,1.2741)	<.0001	1.22	(1.1639,1.2789)	<.0001	1.084	(1.0434,1.1257)	<.0001
Any CVD	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.03	(0.9911,1.0706)	0.1321	1.06	(1.0188,1.1039)	0.0041	1.064	(1.0226,1.1081)	0.0023
Mirtazapine	1.092	(1.0504,1.1352)	<.0001	1.117	(1.0728,1.1621)	<.0001	1.072	(1.0217,1.1241)	0.0045
Tricyclics	1.109	(1.0671,1.1515)	<.0001	1.139	(1.0962,1.1845)	<.0001	1.143	(1.0996,1.1883)	<.0001

All-Cause Mortality Hazard Ratio (reference group Prazosin)

Mortality	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.652	(1.5952,1.7099)	<.0001	1.55	(1.4973,1.6053)	<.0001	1.566	(1.5127,1.622)	<.0001
Mirtazapine	1.719	(1.6563,1.785)	<.0001	1.408	(1.3561,1.4621)	<.0001	1.399	(1.3472,1.4525)	<.0001
Tricyclics	1.288	(1.2222,1.3578)	<.0001	1.208	(1.1457,1.2734)	<.0001	1.197	(1.1358,1.2625)	<.0001
Mortality	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.739	(1.6754,1.8048)	<.0001	1.75	(1.6856,1.8159)	<.0001	1.387	(1.3335,1.4436)	<.0001
Mirtazapine	1.463	(1.4067,1.5211)	<.0001	1.359	(1.297,1.4244)	<.0001	1.299	(1.2473,1.3537)	<.0001
Tricyclics	1.248	(1.1835,1.317)	<.0001	1.255	(1.1895,1.3236)	<.0001	1.149	(1.1022,1.1977)	<.0001
Mortality	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.458	(1.4013,1.5172)	<.0001	1.608	(1.5424,1.6762)	<.0001	1.618	(1.5523,1.6871)	<.0001
Mirtazapine	1.323	(1.2703,1.3788)	<.0001	1.376	(1.319,1.4353)	<.0001	1.273	(1.2111,1.3378)	<.0001
Tricyclics	1.151	(1.1043,1.2002)	<.0001	1.186	(1.1373,1.2376)	<.0001	1.193	(1.1434,1.2443)	<.0001

Tables - CVD and Mortality Sensitivity Analysis Using All Available Post-Index Data

For all subsequent model tables:

Model 0: Unadjusted

Model 1: Adjusted for sociodemographics, comorbidities, prescribing facility factors, service utilization factors

Model 2: Adding days on index medication

Model 3: Model 1 covariates + days on index med + other augmenting classes

Model 4: Model 1 covariates + days on index med + other augmenting classes + dose of augmenting med

Model 5: Propensity weighted

Model 6: Propensity weighted + days on index med

Model 7: Propensity weighted + days on index med + other augmenting classes

Model 8: Propensity weighted + days on index med + other augmenting classes + dose of augmenting med

Death as competing risk and censored at 12/31/2015

Myocardial Infarction Hazard Ratio (reference group Prazosin)

MI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.105	(1.0151,1.2032)	0.0212	1.049	(0.9635,1.1428)	0.2687	1.049	(0.9633,1.143)	0.2697
Mirtazapine	1.284	(1.1734,1.4044)	<.0001	1.103	(1.0072,1.2077)	0.0345	1.103	(1.0071,1.2078)	0.0346
Tricyclics	1.303	(1.1583,1.4651)	<.0001	1.217	(1.0814,1.3692)	0.0011	1.217	(1.0813,1.3694)	0.0011
MI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.054	(0.9634,1.1539)	0.2504	1.057	(0.966,1.1571)	0.2265	1.004	(0.9117,1.1059)	0.9336
Mirtazapine	1.138	(1.0346,1.2513)	0.0078	1.1	(0.9811,1.2343)	0.1023	1.073	(0.9738,1.1823)	0.1545
Tricyclics	1.241	(1.1008,1.3991)	0.0004	1.244	(1.1033,1.4022)	0.0004	1.064	(0.9664,1.1719)	0.2058
MI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.022	(0.928,1.1264)	0.6536	1.021	(0.9238,1.1282)	0.685	1.022	(0.9249,1.1296)	0.668
Mirtazapine	1.089	(0.9878,1.1997)	0.0868	1.128	(1.0204,1.2477)	0.0186	1.113	(0.9877,1.2535)	0.0791
Tricyclics	1.095	(0.9939,1.206)	0.0663	1.121	(1.0154,1.2369)	0.0236	1.122	(1.0164,1.2381)	0.0224

Coronary Artery Bypass Graft Hazard Ratio (reference group Prazosin)

CABG	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.014	(0.8937,1.1505)	0.8288	0.972	(0.8567,1.1038)	0.6655	0.975	(0.8592,1.1072)	0.6995
Mirtazapine	1.213	(1.063,1.3852)	0.0042	1.053	(0.9216,1.2042)	0.4454	1.051	(0.9197,1.2018)	0.4631
Tricyclics	1.429	(1.2116,1.6844)	<.0001	1.377	(1.1668,1.6257)	0.0002	1.374	(1.1632,1.6224)	0.0002
CABG	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	0.979	(0.8571,1.1183)	0.7547	0.979	(0.8568,1.1186)	0.7551	0.981	(0.8492,1.1331)	0.7936
Mirtazapine	1.066	(0.9274,1.2243)	0.3699	1.066	(0.9019,1.2595)	0.4543	1.077	(0.9329,1.2437)	0.311
Tricyclics	1.396	(1.1781,1.6541)	0.0001	1.396	(1.178,1.6543)	0.0001	1.241	(1.0813,1.4254)	0.0021
CABG	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	0.996	(0.8616,1.1502)	0.9513	1.019	(0.8784,1.1812)	0.807	1.019	(0.8785,1.1822)	0.8026
Mirtazapine	1.095	(0.9482,1.264)	0.217	1.145	(0.9879,1.3261)	0.0723	1.138	(0.9563,1.3553)	0.145
Tricyclics	1.28	(1.1134,1.4705)	0.0005	1.329	(1.1527,1.5319)	<.0001	1.329	(1.1528,1.5328)	<.0001

Percutaneous Coronary Intervention Hazard Ratio (reference group Prazosin)

PCI	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.019	(0.9465,1.0967)	0.6199	0.988	(0.9173,1.0636)	0.744	0.986	(0.9158,1.0623)	0.716
Mirtazapine	1.123	(1.0375,1.2158)	0.0041	0.987	(0.9109,1.0694)	0.7486	0.988	(0.9118,1.0704)	0.7663
Tricyclics	1.288	(1.165,1.4245)	<.0001	1.241	(1.1221,1.3734)	<.0001	1.243	(1.1234,1.375)	<.0001
PCI	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	0.99	(0.9154,1.0714)	0.8086	0.997	(0.9212,1.0784)	0.9339	0.974	(0.8955,1.0596)	0.5413
Mirtazapine	1.004	(0.9232,1.0913)	0.9305	0.929	(0.8412,1.0269)	0.1503	0.994	(0.9129,1.0831)	0.8975
Tricyclics	1.269	(1.145,1.4061)	<.0001	1.275	(1.1508,1.4132)	<.0001	1.125	(1.0358,1.2214)	0.0052
PCI	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	0.991	(0.9111,1.0789)	0.8416	0.991	(0.9074,1.0817)	0.8352	0.996	(0.912,1.0873)	0.9246
Mirtazapine	1.009	(0.9258,1.0987)	0.8451	1.023	(0.9366,1.1175)	0.6131	0.963	(0.8686,1.0685)	0.4801
Tricyclics	1.157	(1.0648,1.2561)	0.0006	1.179	(1.084,1.2829)	0.0001	1.184	(1.0884,1.2882)	<.0001

Heart Failure Hazard Ratio (reference group Prazosin)

HF	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.162	(1.0802,1.2502)	<.0001	1.07	(0.9937,1.1525)	0.0732	1.065	(0.9891,1.1478)	0.0948
Mirtazapine	1.438	(1.3326,1.5516)	<.0001	1.147	(1.0616,1.2399)	0.0005	1.15	(1.0644,1.2433)	0.0004
Tricyclics	1.396	(1.2641,1.5422)	<.0001	1.231	(1.1121,1.3624)	<.0001	1.235	(1.1159,1.3672)	<.0001
HF	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.086	(1.0043,1.1745)	0.0387	1.09	(1.0081,1.1792)	0.0307	1.029	(0.9482,1.1174)	0.4904
Mirtazapine	1.173	(1.0811,1.2716)	0.0001	1.12	(1.0147,1.236)	0.0245	1.103	(1.0154,1.1976)	0.0202
Tricyclics	1.268	(1.1438,1.4058)	<.0001	1.272	(1.1476,1.4106)	<.0001	1.082	(0.9968,1.1742)	0.0596
HF	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.042	(0.959,1.1328)	0.3293	1.08	(0.9905,1.1772)	0.0812	1.084	(0.994,1.1816)	0.0682
Mirtazapine	1.129	(1.0383,1.2265)	0.0044	1.152	(1.0568,1.255)	0.0013	1.104	(0.9958,1.2231)	0.0603
Tricyclics	1.115	(1.0259,1.211)	0.0104	1.152	(1.0586,1.2539)	0.001	1.156	(1.0619,1.258)	0.0008

Unstable Angina Hazard Ratio (reference group Prazosin)

Unstable Angina	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.187	(0.995,1.416)	0.0569	1.126	(0.9432,1.3432)	0.1895	1.118	(0.9356,1.3354)	0.2199
Mirtazapine	1.175	(0.9683,1.4256)	0.1024	1.008	(0.8297,1.2238)	0.9384	1.012	(0.8333,1.2302)	0.9008
Tricyclics	1.532	(1.2133,1.935)	0.0003	1.449	(1.1456,1.8325)	0.002	1.457	(1.1523,1.8428)	0.0017
Unstable Angina	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.102	(0.9122,1.3303)	0.3148	1.118	(0.9261,1.3504)	0.2453	1.089	(0.8903,1.3332)	0.4054
Mirtazapine	1.059	(0.8638,1.2974)	0.583	0.849	(0.6709,1.0737)	0.1715	1.012	(0.8221,1.2468)	0.9075
Tricyclics	1.535	(1.2086,1.9504)	0.0004	1.557	(1.2257,1.9779)	0.0003	1.261	(1.0353,1.5354)	0.0212
Unstable Angina	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.098	(0.8962,1.3454)	0.3669	1.054	(0.8545,1.3002)	0.623	1.07	(0.8677,1.3204)	0.5252
Mirtazapine	1.026	(0.8326,1.2637)	0.8112	1.095	(0.882,1.3604)	0.4097	0.877	(0.6853,1.1217)	0.2954
Tricyclics	1.301	(1.0687,1.5846)	0.0088	1.374	(1.1227,1.6823)	0.0021	1.395	(1.1392,1.7072)	0.0013

Stroke Hazard Ratio (reference group Prazosin)

Stroke	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.217	(1.0833,1.3679)	0.0009	1.146	(1.0195,1.289)	0.0224	1.145	(1.0181,1.2883)	0.0239
Mirtazapine	1.216	(1.0693,1.382)	0.0028	1.029	(0.9034,1.1712)	0.6705	1.029	(0.9038,1.172)	0.664
Tricyclics	1.2	(1.013,1.4225)	0.0349	1.133	(0.9546,1.3444)	0.1531	1.134	(0.9551,1.3459)	0.1513
Stroke	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.151	(1.0163,1.3037)	0.0268	1.158	(1.0224,1.3114)	0.021	1.068	(0.9349,1.219)	0.3344
Mirtazapine	1.005	(0.8771,1.1506)	0.9473	0.932	(0.79,1.0984)	0.3988	0.994	(0.8663,1.1405)	0.931
Tricyclics	1.125	(0.946,1.3382)	0.1828	1.131	(0.9509,1.345)	0.1644	0.998	(0.8712,1.1439)	0.9805
Stroke	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.085	(0.9496,1.2395)	0.2306	1.097	(0.9548,1.2597)	0.1914	1.103	(0.9601,1.2668)	0.1665
Mirtazapine	1.01	(0.88,1.1592)	0.8874	0.988	(0.8571,1.1391)	0.8686	0.922	(0.7766,1.0938)	0.3505
Tricyclics	1.031	(0.8994,1.183)	0.6573	1.03	(0.8962,1.1834)	0.678	1.035	(0.9007,1.1895)	0.6272

Any Cardiovascular Event Hazard Ratio (reference group Prazosin)

Any CVD	Model 0			Model 1			Model 2		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.099	(1.0498,1.1503)	<.0001	1.043	(0.9958,1.0924)	0.0746	1.04	(0.9932,1.0899)	0.0942
Mirtazapine	1.256	(1.1967,1.3189)	<.0001	1.063	(1.0116,1.1168)	0.0156	1.065	(1.0131,1.1185)	0.0133
Tricyclics	1.302	(1.2222,1.3872)	<.0001	1.22	(1.1442,1.301)	<.0001	1.223	(1.1464,1.3037)	<.0001
Any CVD	Model 3			Model 4			Model 5		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.056	(1.0058,1.1098)	0.0286	1.062	(1.0113,1.116)	0.016	1.007	(0.9562,1.0611)	0.7844
Mirtazapine	1.082	(1.0274,1.1392)	0.0029	1.01	(0.9488,1.075)	0.7561	1.041	(0.9878,1.0974)	0.1325
Tricyclics	1.249	(1.17,1.3331)	<.0001	1.254	(1.1752,1.3391)	<.0001	1.086	(1.0317,1.144)	0.0017
Any CVD	Model 6			Model 7			Model 8		
	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val	Diff to Ref	95%CI	p-val
Antipsychotics	1.024	(0.9713,1.0793)	0.3805	1.05	(0.9943,1.1096)	0.079	1.056	(0.9992,1.1152)	0.0534
Mirtazapine	1.063	(1.0077,1.1206)	0.0248	1.084	(1.0261,1.145)	0.004	1.02	(0.9557,1.0885)	0.5519
Tricyclics	1.118	(1.0609,1.1777)	<.0001	1.148	(1.0888,1.2114)	<.0001	1.153	(1.0932,1.2164)	<.0001